Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Molly Gilligan

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cancer Metastasis Reviews|December 22, 2019
PrefaceDipak Panigrahy, Molly Gilligan
Cancer Metastasis Reviews|February 10, 2020
PrefaceDipak Panigrahy, Molly Gilligan
Leukemia & Lymphoma|October 24, 2025
Beyond "favorable": early molecular response and outcomes in pediatric RUNX1::RUNX1T1 AMLMolly Gilligan, Alexandra Gomez-Arteaga
Leukemia & Lymphoma|June 7, 2026
When molecular response is enough: complete molecular response and the role of allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive ALLMolly Gilligan, Alexandra Gomez-Arteaga
Hemasphere|March 21, 2024
Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myelomaGeorge Mellgard, Molly Gilligan, Edward R Scheffer Cliff, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cancer Metastasis Reviews|December 22, 2019
PrefaceDipak Panigrahy, Molly Gilligan
Cancer Metastasis Reviews|February 10, 2020
PrefaceDipak Panigrahy, Molly Gilligan
Leukemia & Lymphoma|October 24, 2025
Beyond "favorable": early molecular response and outcomes in pediatric RUNX1::RUNX1T1 AMLMolly Gilligan, Alexandra Gomez-Arteaga
Leukemia & Lymphoma|June 7, 2026
When molecular response is enough: complete molecular response and the role of allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive ALLMolly Gilligan, Alexandra Gomez-Arteaga
Hemasphere|March 21, 2024
Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myelomaGeorge Mellgard, Molly Gilligan, Edward R Scheffer Cliff, et al.
Pageof 1